Shanghai Junshi: Placing Coverage Under Review

Yurou Zheng Aug 11, 2023

Securities in This Article

We are placing coverage of narrow-moat-rated Shanghai Junshi 01877 under review pending the transfer of coverage to a new analyst. We expect to revisit our coverage of this company over the next three months. Our most recent fair value estimate was HKD 45.50.

The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar’s editorial policies.

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

United States

Shanghai Junshi: Placing Coverage Under Review

4 Stocks to Buy Before They Rise Further

2 Undervalued Stocks to Buy Before They Rebound

The 10 Best Dividend Stocks

12 Best Blue-Chip Stocks to Buy for the Long Term

The Best Equity ETFs

Innovent Biologics: Transferring Coverage, Moat Rating Lowered to None, Fair Value Estimate Unchanged

WuXi Biologics: Upgraded to Narrow Moat Rating; Shares Undervalued

RemeGen: Placing Coverage Under Review

Sinopharm: Placing Coverage Under Review

China Resources Pharma: Placing Coverage Under Review

Shanghai Pharmaceuticals: Placing Coverage Under Review

Sino Biopharmaceutical: Placing Coverage Under Review

Shanghai Junshi: Placing Coverage Under Review

Genscript Biotech: Placing Coverage Under Review

3SBio: Placing Coverage Under Review

Sponsor Center

What We Do

Company

Get Help